Tongzhen Xu, Lingling Feng, Wenjue Zhang, Haoyue Li, Huiying Ma, Muyasha Abulimiti, Yutong Tan, Feiyan Deng, Wenting Huang, Shuangmei Zou, Wenyan Kang, Liming Jiang, Ying Wang, Chen Hu, Yinggang Chen, Haitao Zhou, Yuan Tang, Jing Jin
BACKGROUND: For patients with locally advanced rectal cancer (LARC), total neoadjuvant therapy (TNT), namely, intensifying preoperative treatment through the integration of radiotherapy and systemic chemotherapy before surgery, was commonly recommended as the standard treatment. However, the risk of distant metastasis at 3 years remained higher than 20%, and the complete response (CR) rate was less than 30%. Several clinical trials had suggested a higher complete response rate when combining single-agent immunotherapy with short-course radiotherapy (SCRT)...
April 19, 2024: BMC Cancer